James E. Polli - Publications

Affiliations: 
Pharmaceutical Sciences University of Maryland School of Medicine, Baltimore, MD, United States 
Area:
Pharmacy, Public Health, Epidemiology

124 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Zhu P, Ye Z, Guo D, Xiong Z, Huang S, Guo J, Zhang W, Polli JE, Zhou H, Li Q, Shu Y. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharmaceutical Research. 35: 243. PMID 30361780 DOI: 10.1007/s11095-018-2526-y  0.4
2018 Metry M, Felton J, Cheng K, Xu S, Ai Y, Xue F, Raufman JP, Polli JE. Attenuated Accumulation of Novel Fluorine (19F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice. Molecular Pharmaceutics. PMID 30247920 DOI: 10.1021/acs.molpharmaceut.8b00454  0.36
2018 Guo D, Yang H, Li Q, Bae HJ, Obianom O, Zeng S, Su T, Polli JE, Shu Y. Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharmaceutical Research. 35: 204. PMID 30191328 DOI: 10.1007/s11095-018-2486-2  0.4
2018 Cheng K, Metry M, Felton J, Shang AC, Drachenberg CB, Xu S, Zhan M, Schumacher J, Guo GL, Polli JE, Raufman JP. Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice. Oncotarget. 9: 25572-25585. PMID 29876009 DOI: 10.18632/oncotarget.25385  0.36
2016 Felton J, Cheng K, Said A, Shang AC, Xu S, Vivian D, Metry M, Polli JE, Raufman JP. Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport. Journal of Visualized Experiments : Jove. PMID 27929465 DOI: 10.3791/54597  1
2016 Vaithianathan S, Ting TY, Jiang W, Polli JE. Release of levetiracetam from extended-release tablets that appear intact in patient stool. Seizure. 40: 7-9. PMID 27269879 DOI: 10.1016/j.seizure.2016.05.011  1
2016 Raman S, Polli JE. Prediction of Positive Food Effect: Bioavailability Enhancement of BCS Class II Drugs. International Journal of Pharmaceutics. PMID 27067239 DOI: 10.1016/j.ijpharm.2016.04.013  1
2016 Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag SW, Flasar MH, Ting TY, Polli JE. Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs". Journal of Pharmaceutical Sciences. 105: 1355-7. PMID 27019956 DOI: 10.1016/j.xphs.2016.02.028  1
2016 Goodarzi N, Barazesh Morgani A, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Mehta MU, Polli JE, Shah VP, Dressman JB. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. Journal of Pharmaceutical Sciences. PMID 26952879 DOI: 10.1016/j.xphs.2016.01.017  1
2016 Li Q, Yang H, Guo D, Zhang TL, Polli JE, Zhou HH, Shu Y. Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 26825640 DOI: 10.1124/dmd.115.067223  0.4
2015 Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag SW, Flasar MH, Ting TY, Polli JE. Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. Journal of Pharmaceutical Sciences. PMID 26375604 DOI: 10.1002/jps.24643  1
2015 Raufman JP, Dawson PA, Rao A, Drachenberg CB, Heath J, Shang AC, Hu S, Zhan M, Polli JE, Cheng K. Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis. 36: 1193-200. PMID 26210740 DOI: 10.1093/carcin/bgv107  1
2015 Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. Epilepsia. PMID 26201987 DOI: 10.1111/epi.13095  1
2015 Donovan MD, Polli JE, Langguth P, Tamai I, Vig B, Yu LX. Gordon L. Amidon: Very Sustained Drug Absorption. Journal of Pharmaceutical Sciences. PMID 26053319 DOI: 10.1002/jps.24523  1
2015 Vaithianathan S, Raman S, Jiang W, Ting TY, Kane MA, Polli JE. Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets. Molecular Pharmaceutics. 12: 2436-43. PMID 26001027 DOI: 10.1021/acs.molpharmaceut.5b00154  1
2015 Petruševska M, Berglez S, Krisch I, Legen I, Megušar K, Peternel L, Abrahamsson B, Cristofoletti R, Groot DW, Kopp S, Langguth P, Mehta M, Polli JE, Shah VP, Dressman J. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam. Journal of Pharmaceutical Sciences. PMID 25663270 DOI: 10.1002/jps.24350  1
2015 Dong Z, Li Q, Guo D, Shu Y, Polli JE. Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. Journal of Pharmaceutical Sciences. PMID 25645375 DOI: 10.1002/jps.24375  0.4
2015 Dong Z, Ekins S, Polli JE. A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. International Journal of Pharmaceutics. 478: 88-95. PMID 25448570 DOI: 10.1016/j.ijpharm.2014.11.022  1
2015 Kona R, Fahmy RM, Claycamp G, Polli JE, Martinez M, Hoag SW. Quality-by-design III: application of near-infrared spectroscopy to monitor roller compaction in-process and product quality attributes of immediate release tablets. Aaps Pharmscitech. 16: 202-16. PMID 25319052 DOI: 10.1208/s12249-014-0180-1  1
2015 Wong JM, Jones JW, Jiang W, Polli JE, Kane MA. Quantification of lamotrigine in patient plasma using a fast liquid chromatography-tandem mass spectrometry method with backflush technology. Therapeutic Drug Monitoring. 37: 188-97. PMID 25162213 DOI: 10.1097/FTD.0000000000000123  1
2014 Selen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, Martinez MN, Lennernäs H, Wigal TL, Swinney DC, Polli JE, Serajuddin AT, Cook JA, Dressman JB. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. Journal of Pharmaceutical Sciences. 103: 3377-97. PMID 25256402 DOI: 10.1002/jps.24162  1
2014 Dong Z, Ekins S, Polli JE. Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 66: 1-9. PMID 25220493 DOI: 10.1016/j.ejps.2014.09.005  1
2014 Vivian D, Polli JE. Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver. International Journal of Pharmaceutics. 475: 597-604. PMID 25219859 DOI: 10.1016/j.ijpharm.2014.09.014  1
2014 Vivian D, Cheng K, Khurana S, Xu S, Dawson PA, Raufman JP, Polli JE. Design and evaluation of a novel trifluorinated imaging agent for assessment of bile acid transport using fluorine magnetic resonance imaging. Journal of Pharmaceutical Sciences. 103: 3782-92. PMID 25196788 DOI: 10.1002/jps.24131  1
2014 Vivian D, Polli JE. Mechanistic interpretation of conventional Michaelis-Menten parameters in a transporter system. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 64: 44-52. PMID 25169756 DOI: 10.1016/j.ejps.2014.08.007  1
2014 Dahan A, Wolk O, Zur M, Amidon GL, Abrahamsson B, Cristofoletti R, Groot DW, Kopp S, Langguth P, Polli JE, Shah VP, Dressman JB. Biowaiver monographs for immediate-release solid oral dosage forms: codeine phosphate. Journal of Pharmaceutical Sciences. 103: 1592-600. PMID 24788239 DOI: 10.1002/jps.23977  1
2014 Vivian D, Cheng K, Khurana S, Xu S, Kriel EH, Dawson PA, Raufman JP, Polli JE. In vivo performance of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile acid transport. Molecular Pharmaceutics. 11: 1575-82. PMID 24708306 DOI: 10.1021/mp400740c  1
2014 Gandhi SV, Rodriguez W, Khan M, Polli JE. Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs. Aaps Pharmscitech. 15: 601-11. PMID 24557773 DOI: 10.1208/s12249-014-0084-0  1
2014 Garzel B, Yang H, Zhang L, Huang SM, Polli JE, Wang H. The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 318-22. PMID 24335466 DOI: 10.1124/dmd.113.054189  1
2014 González PM, Lagos CF, Ward WC, Polli JE. Structural requirements of the human sodium-dependent bile acid transporter (hASBT): role of 3- and 7-OH moieties on binding and translocation of bile acids. Molecular Pharmaceutics. 11: 588-98. PMID 24328955 DOI: 10.1021/mp400575t  1
2014 Shohin IE, Kulinich JI, Ramenskaya GV, Abrahamsson B, Kopp S, Langguth P, Polli JE, Shah VP, Groot DW, Barends DM, Dressman JB. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam. Journal of Pharmaceutical Sciences. 103: 367-77. PMID 24301077 DOI: 10.1002/jps.23799  1
2014 Van Buskirk GA, Shah V, Yacobi A, Bolger MB, Chittenden J, Davit BM, Destefano A, Dressman J, Duan JZ, Ganes DA, González MA, Gray V, Kakhi M, Li R, Mirza T, ... Polli JE, et al. Application of IVIVC in formulation development Dissolution Technologies. 21: 51-58. DOI: 10.14227/DT210214P51  1
2013 Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM, Polli JE, Shu Y. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicology and Applied Pharmacology. 273: 100-9. PMID 24001450 DOI: 10.1016/j.taap.2013.08.024  1
2013 Soares KC, Rediguieri CF, Souza J, Serra CH, Abrahamsson B, Groot DW, Kopp S, Langguth P, Polli JE, Shah VP, Dressman J. Biowaiver monographs for immediate-release solid oral dosage forms: Zidovudine (azidothymidine). Journal of Pharmaceutical Sciences. 102: 2409-23. PMID 23754446 DOI: 10.1002/jps.23624  1
2013 Li Q, Yang H, Peng X, Guo D, Dong Z, Polli JE, Shu Y. Ischemia/Reperfusion-inducible protein modulates the function of organic cation transporter 1 and multidrug and toxin extrusion 1. Molecular Pharmaceutics. 10: 2578-87. PMID 23651427 DOI: 10.1021/mp400013t  1
2013 Claro da Silva T, Polli JE, Swaan PW. The solute carrier family 10 (SLC10): beyond bile acid transport. Molecular Aspects of Medicine. 34: 252-69. PMID 23506869 DOI: 10.1016/j.mam.2012.07.004  1
2013 Dong Z, Ekins S, Polli JE. Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Molecular Pharmaceutics. 10: 1008-19. PMID 23339484 DOI: 10.1021/mp300453k  1
2013 Vivian D, Cheng K, Khurana S, Xu S, Whiterock V, Witter D, Lentz KA, Santone KS, Raufman JP, Polli JE. Design and characterization of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile Acid transporter activity. Pharmaceutical Research. 30: 1240-51. PMID 23319170 DOI: 10.1007/s11095-012-0963-6  1
2013 Cristofoletti R, Nair A, Abrahamsson B, Groot DW, Kopp S, Langguth P, Polli JE, Shah VP, Dressman JB. Biowaiver monographs for immediate release solid oral dosage forms: efavirenz. Journal of Pharmaceutical Sciences. 102: 318-29. PMID 23175470 DOI: 10.1002/jps.23380  1
2012 Ekins S, Polli JE, Swaan PW, Wright SH. Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition Clinical Pharmacology and Therapeutics. 92: 661-665. PMID 23010651 DOI: 10.1038/clpt.2012.164  1
2012 Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, Shah VP, Dressman JB. Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride. Journal of Pharmaceutical Sciences. 101: 4390-401. PMID 22949374 DOI: 10.1002/jps.23312  1
2012 Shohin IE, Kulinich JI, Ramenskaya GV, Abrahamsson B, Kopp S, Langguth P, Polli JE, Shah VP, Groot DW, Barends DM, Dressman JB. Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen. Journal of Pharmaceutical Sciences. 101: 3593-603. PMID 22786667 DOI: 10.1002/jps.23233  1
2012 Nair AK, Anand O, Chun N, Conner DP, Mehta MU, Nhu DT, Polli JE, Yu LX, Davit BM. Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA. The Aaps Journal. 14: 664-6. PMID 22718306 DOI: 10.1208/s12248-012-9384-z  1
2012 Polli JE, Cook JA, Davit BM, Dickinson PA, Argenti D, Barbour N, García-Arieta A, Geoffroy JM, Hartauer K, Li S, Mitra A, Muller FX, Purohit V, Sanchez-Felix M, Skoug JW, et al. Summary workshop report: Facilitating oral product development and reducing regulatory burden through novel approaches to assess bioavailability/bioequivalence. The Aaps Journal. 14: 627-38. PMID 22684402 DOI: 10.1208/s12248-012-9376-z  1
2012 Dressman JB, Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Langguth P, Polli JE, Shah VP, Zimmer M. Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid. Journal of Pharmaceutical Sciences. 101: 2653-67. PMID 22674043 DOI: 10.1002/jps.23212  1
2012 Kolhatkar V, Polli JE. Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 46: 86-99. PMID 22387310 DOI: 10.1016/j.ejps.2012.02.012  1
2012 González PM, Hussainzada N, Swaan PW, Mackerell AD, Polli JE. Putative irreversible inhibitors of the human sodium-dependent bile acid transporter (hASBT; SLC10A2) support the role of transmembrane domain 7 in substrate binding/translocation. Pharmaceutical Research. 29: 1821-31. PMID 22354836 DOI: 10.1007/s11095-012-0706-8  1
2012 Ekins S, Diao L, Polli JE. A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. Molecular Pharmaceutics. 9: 905-13. PMID 22339151 DOI: 10.1021/mp200438v  1
2012 Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, Shah VP, Dressman JB. Biowaiver monographs for immediate-release solid oral dosage forms: primaquine phosphate. Journal of Pharmaceutical Sciences. 101: 936-45. PMID 22161739 DOI: 10.1002/jps.23006  1
2012 Kolhatkar V, Diao L, Acharya C, Mackerell AD, Polli JE. Identification of novel nonsteroidal compounds as substrates or inhibitors of hASBT. Journal of Pharmaceutical Sciences. 101: 116-26. PMID 22109685 DOI: 10.1002/jps.22728  1
2012 Strauch S, Dressman JB, Shah VP, Kopp S, Polli JE, Barends DM. Biowaiver monographs for immediate-release solid oral dosage forms: quinine sulfate. Journal of Pharmaceutical Sciences. 101: 499-508. PMID 22081435 DOI: 10.1002/jps.22810  1
2012 Ritchie GE, Ciurczak EW, Flank S, Hoag SW, Polli JE. Risk and reputation: A science and risk-based approach to brand protection Pharmaceutical Engineering. 32: 20-30.  1
2011 da Silva TC, Hussainzada N, Khantwal CM, Polli JE, Swaan PW. Transmembrane helix 1 contributes to substrate translocation and protein stability of bile acid transporter SLC10A2. The Journal of Biological Chemistry. 286: 27322-32. PMID 21646357 DOI: 10.1074/jbc.M110.217802  1
2011 Diao L, Polli JE. Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2. Journal of Pharmaceutical Sciences. 100: 3802-16. PMID 21455979 DOI: 10.1002/jps.22557  1
2011 Rais R, Fletcher S, Polli JE. Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). Journal of Pharmaceutical Sciences. 100: 1184-95. PMID 20848648 DOI: 10.1002/jps.22332  1
2011 Acharya C, Coop A, Polli JE, Mackerell AD. Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Current Computer-Aided Drug Design. 7: 10-22. PMID 20807187 DOI: 10.2174/157340911793743547  1
2010 Zheng X, Pan Y, Acharya C, Swaan PW, Polli JE. Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid. Bioconjugate Chemistry. 21: 2038-48. PMID 20968316 DOI: 10.1021/bc100273w  1
2010 Rais R, Acharya C, MacKerell AD, Polli JE. Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates Molecular Pharmaceutics. 7: 2240-2254. PMID 20939504 DOI: 10.1021/mp100233v  1
2010 Diao L, Ekins S, Polli JE. Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Molecular Pharmaceutics. 7: 2120-31. PMID 20831193 DOI: 10.1021/mp100226q  1
2010 Cook JA, Davit BM, Polli JE. Impact of Biopharmaceutics Classification System-based biowaivers. Molecular Pharmaceutics. 7: 1539-44. PMID 20735084 DOI: 10.1021/mp1001747  1
2010 Kolhatkar V, Polli JE. Reliability of inhibition models to correctly identify type of inhibition. Pharmaceutical Research. 27: 2433-45. PMID 20711748 DOI: 10.1007/s11095-010-0236-1  1
2010 Zheng X, Polli JE. Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT. International Journal of Pharmaceutics. 396: 111-8. PMID 20600720 DOI: 10.1016/j.ijpharm.2010.06.039  1
2010 Zheng X, Diao L, Ekins S, Polli JE. Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies. Biochemical Pharmacology. 80: 1087-92. PMID 20599790 DOI: 10.1016/j.bcp.2010.06.012  1
2010 Selen A, Cruañes MT, Müllertz A, Dickinson PA, Cook JA, Polli JE, Kesisoglou F, Crison J, Johnson KC, Muirhead GT, Schofield T, Tsong Y. Meeting report: Applied biopharmaceutics and quality by design for dissolution/release specification setting: Product quality for patient benefit Aaps Journal. 12: 465-472. PMID 20517660 DOI: 10.1208/s12248-010-9206-0  1
2010 Rais R, Acharya C, Tririya G, MacKerell AD, Polli JE. Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter Journal of Medicinal Chemistry. 53: 4749-4760. PMID 20504026 DOI: 10.1021/jm1003683  1
2010 Diao L, Shu Y, Polli JE. Uptake of pramipexole by human organic cation transporters. Molecular Pharmaceutics. 7: 1342-7. PMID 20496886 DOI: 10.1021/mp100036b  1
2010 Bahadduri PM, Polli JE, Swaan PW, Ekins S. Targeting drug transporters - combining in silico and in vitro approaches to predict in vivo. Methods in Molecular Biology (Clifton, N.J.). 637: 65-103. PMID 20419430 DOI: 10.1007/978-1-60761-700-6_4  1
2010 Teksin ZS, Seo PR, Polli JE. Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. The Aaps Journal. 12: 238-41. PMID 20224985 DOI: 10.1208/s12248-010-9176-2  1
2010 Green G, Berg C, Polli JE, Barends DM, Brown WE. Pharmacopeial standards for the subdivision characteristics of scored tablets Pharma Times. 42: 15-24.  1
2010 Green G, Berg C, Polli JE, Barends DM, Brown WE. Pharmacopeial standards for the subdivision characteristics of scored tablets Pharma Times. 42: 15-24.  1
2009 Zheng X, Ekins S, Raufman JP, Polli JE. Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Molecular Pharmaceutics. 6: 1591-603. PMID 19673539 DOI: 10.1021/mp900163d  1
2009 Diao L, Ekins S, Polli JE. Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharmaceutical Research. 26: 1890-900. PMID 19437106 DOI: 10.1007/s11095-009-9905-3  1
2009 González PM, Acharya C, MacKerell AD, Polli JE. Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids Pharmaceutical Research. 26: 1665-1678. PMID 19384469 DOI: 10.1007/s11095-009-9877-3  1
2009 Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium Journal of Pharmaceutical Sciences. 98: 1206-1219. PMID 18752289 DOI: 10.1002/jps.21525  1
2009 Polli JE, Hoag SW, Flank S. Near-infrared spectrophotometric: Comparison of authentic and suspect pharmaceuticals Pharmaceutical Technology. 33: 46-52.  1
2009 Hauck WW, DeStefano AJ, Brown WE, Stippler E, Abernethy DR, Williams RL, Foster TS, Polli JE, Burgess DJ, Bryan Crist G, Gonzalez MA, Gray VA, Kraemer J, Leeson LJ, Parr AF, et al. Description of the upcoming change in data analysis for USP dissolution performance verification tests Dissolution Technologies. 16: 7-12.  1
2009 Hauck WW, DeStefano AJ, Brown WE, Stippler E, Abernethy DR, Williams RL, Foster TS, Polli JE, Burgess DJ, Bryan Crist G, Gonzalez MA, Gray VA, Kraemer J, Leeson LJ, Parr AF, et al. Description of the upcoming change in data analysis for USP dissolution performance verification tests Dissolution Technologies. 16: 7-12.  1
2008 Rais R, Gonzalez PM, Zheng X, Wring SA, Polli JE. Method to screen substrates of apical sodium-dependent bile acid transporter. The Aaps Journal. 10: 596-605. PMID 19085111 DOI: 10.1208/s12248-008-9069-9  1
2008 Acharya C, Seo PR, Polli JE, MacKerell AD. Computational model for predicting chemical substituent effects on passive drug permeability across parallel artificial membranes Molecular Pharmaceutics. 5: 818-828. PMID 18710255 DOI: 10.1021/mp800035h  1
2008 Polli JE, Abrahamsson BS, Yu LX, Amidon GL, Baldoni JM, Cook JA, Fackler P, Hartauer K, Johnston G, Krill SL, Lipper RA, Malick WA, Shah VP, Sun D, Winkle HN, et al. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. The Aaps Journal. 10: 373-9. PMID 18679807 DOI: 10.1208/s12248-008-9040-9  1
2008 Polli JE. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms. The Aaps Journal. 10: 289-99. PMID 18500564 DOI: 10.1208/s12248-008-9027-6  1
2008 González P, Polli JE. Impact of impurity on kinetic estimates from transport and inhibition studies. The Journal of Pharmacology and Experimental Therapeutics. 326: 296-305. PMID 18443216 DOI: 10.1124/jpet.107.135863  1
2008 Benet LZ, Amidon GL, Barends DM, Lennernäs H, Polli JE, Shah VP, Stavchansky SA, Yu LX. The use of BDDCS in classifying the permeability of marketed drugs. Pharmaceutical Research. 25: 483-8. PMID 18236138 DOI: 10.1007/s11095-007-9523-x  1
2007 Khandelwal A, Bahadduri PM, Chang C, Polli JE, Swaan PW, Ekins S. Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharmaceutical Research. 24: 2249-62. PMID 17846869 DOI: 10.1007/s11095-007-9435-9  1
2007 Shao J, Polli JE. Evaluation of a novel tablet splitter. Journal of the American Pharmacists Association : Japha. 47: 185-7. PMID 17510006 DOI: 10.1331/P427-7364-V258-9555  1
2007 González-Alvarez I, Fernández-Teruel C, Casabó-Alós VG, Garrigues TM, Polli JE, Ruiz-García A, Bermejo M. In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results. Biopharmaceutics & Drug Disposition. 28: 229-39. PMID 17410527 DOI: 10.1002/bdd.548  1
2007 Balakrishnan A, Hussainzada N, Gonzalez P, Bermejo M, Swaan PW, Polli JE. Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. The Journal of Pharmacology and Experimental Therapeutics. 320: 133-44. PMID 17038509 DOI: 10.1124/jpet.106.107433  1
2006 Chen IJ, Taneja R, Yin D, Seo PR, Young D, MacKerell AD, Polli JE. Chemical substituent effect on pyridine permeability and mechanistic insight from computational molecular descriptors. Molecular Pharmaceutics. 3: 745-55. PMID 17140262 DOI: 10.1021/mp050096+  1
2006 Teksin ZS, Hom K, Balakrishnan A, Polli JE. Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. Journal of Controlled Release : Official Journal of the Controlled Release Society. 116: 50-7. PMID 17049402 DOI: 10.1016/j.jconrel.2006.08.020  1
2006 Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1976-84. PMID 16997908 DOI: 10.1124/dmd.106.012351  1
2006 Balakrishnan A, Wring SA, Polli JE. Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharmaceutical Research. 23: 1451-9. PMID 16783481 DOI: 10.1007/s11095-006-0219-4  1
2006 Seo PR, Teksin ZS, Kao JP, Polli JE. Lipid composition effect on permeability across PAMPA. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 29: 259-68. PMID 16781125 DOI: 10.1016/j.ejps.2006.04.012  1
2006 Balakrishnan A, Wring SA, Coop A, Polli JE. Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter. Molecular Pharmaceutics. 3: 282-92. PMID 16749860 DOI: 10.1021/mp0600135  1
2006 Balakrishnan A, Polli JE. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Molecular Pharmaceutics. 3: 223-30. PMID 16749855 DOI: 10.1021/mp060022d  1
2006 Polli JE. Bile acid disposition and drug pharmacokinetic implications Molecular Pharmaceutics. 3: 197. DOI: 10.1021/mp0600440  1
2005 Balakrishnan A, Sussman DJ, Polli JE. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharmaceutical Research. 22: 1269-80. PMID 16078136 DOI: 10.1007/s11095-005-5274-8  1
2004 Tolle-Sander S, Lentz KA, Maeda DY, Coop A, Polli JE. Increased acyclovir oral bioavailability via a bile acid conjugate. Molecular Pharmaceutics. 1: 40-8. PMID 15832499  1
2004 Balakrishnan A, Rege BD, Amidon GL, Polli JE. Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. Journal of Pharmaceutical Sciences. 93: 2064-75. PMID 15236455 DOI: 10.1002/jps.20118  1
2003 Polli JE, Kim S, Martin BR. Weight uniformity of split tablets required by a Veterans Affairs policy. Journal of Managed Care Pharmacy : Jmcp. 9: 401-7. PMID 14613437  1
2003 Tolle-Sander S, Grill A, Joshi H, Kapil R, Persiani S, Polli JE. Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport. Journal of Pharmaceutical Sciences. 92: 1968-80. PMID 14502537 DOI: 10.1002/jps.10428  1
2002 González MA, Polli JE, Morgan JA. Comments on effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation study. Current Medical Research and Opinion. 18: vii-x. PMID 12487510  1
2002 Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 16: 237-46. PMID 12208453 DOI: 10.1016/S0928-0987(02)00055-6  1
2002 Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research. 19: 921-5. PMID 12180542 DOI: 10.1023/A:1016473601633  1
2002 Seo PR, Shah VP, Polli JE. Novel metrics to compare dissolution profiles. Pharmaceutical Development and Technology. 7: 257-65. PMID 12066580 DOI: 10.1081/PDT-120003493  1
2002 Teng J, Song CK, Williams RL, Polli JE. Lack of medication dose uniformity in commonly split tablets. Journal of the American Pharmaceutical Association (Washington,D.C. : 1996). 42: 195-9. PMID 11926662  1
2002 Tolle-Sander S, Polli JE. Method considerations for Caco-2 permeability assessment in the biopharmaceutics classification system Pharmacopeial Forum. 28: 164-168.  1
2001 Rege BD, Yu Lawrence X, Hussain AS, Polli JE. Effect of common excipients on Caco-2 transport of low-permeability drugs Journal of Pharmaceutical Sciences. 90: 1776-1786. PMID 11745735 DOI: 10.1002/jps.1127  1
2001 Polli JE, McLean AM. Novel direct curve comparison metrics for bioequivalence Pharmaceutical Research. 18: 734-741. PMID 11474775 DOI: 10.1023/A:1011067908500  1
2001 Tajarobi F, El-Sayed M, Rege BD, Polli JE, Ghandehari H. Transport of poly amidoamine dendrimers across Madin-Darby canine kidney cells International Journal of Pharmaceutics. 215: 263-267. PMID 11250111 DOI: 10.1016/S0378-5173(00)00679-7  1
2000 Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharmaceutical Research. 17: 1456-60. PMID 11303953 DOI: 10.1023/A:1007692622216  0.52
2000 Lentz KA, Hayashi J, Lucisano LJ, Polli JE. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. International Journal of Pharmaceutics. 200: 41-51. PMID 10845684 DOI: 10.1016/S0378-5173(00)00334-3  1
2000 Polli JE. IVIVR versus IVIVC Dissolution Technologies. 7. DOI: 10.14227/DT070300P6  1
1999 Ginski MJ, Taneja R, Polli JE. Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system Aaps Pharmsci [Electronic Resource]. 1. PMID 11741200 DOI: 10.1208/ps010203  1
1999 Ginski MJ, Polli JE. Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system International Journal of Pharmaceutics. 177: 117-125. PMID 10205608 DOI: 10.1016/S0378-5173(98)00330-5  1
1999 Polli JE. Dependence of in vitro-in vivo correlation analysis acceptability on model selections Pharmaceutical Development and Technology. 4: 89-96. PMID 10027217 DOI: 10.1081/PDT-100101343  1
1998 Polli JE, Ginski MJ. Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities Pharmaceutical Research. 15: 47-52. PMID 9487545 DOI: 10.1023/A:1011992518592  1
1997 Marston SA, Polli JE. Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence. Pharmaceutical Research. 14: 1363-9. PMID 9358548 DOI: 10.1023/A:1012160419520  1
1997 Polli JE. In vitro-in vivo relationships of several 'immediate' release tablets containing a low permeability drug Advances in Experimental Medicine and Biology. 423: 191-198. PMID 9269495  1
1997 Polli JE, Rekhi GS, Augsburger LL, Shah VP. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets Journal of Pharmaceutical Sciences. 86: 690-700. PMID 9188051 DOI: 10.1021/js960473x  1
1996 Polli JE, Bigora S, Piscitelli DA, Straughn AB, Young D. 'Pavlovian' food effect on the enterohepatic recirculation of piroxicam Biopharmaceutics and Drug Disposition. 17: 635-641. PMID 8894120 DOI: 10.1002/(SICI)1099-081X(199610)17:7<635::AID-BDD981>3.0.CO;2-4  1
1996 Polli JE, Crison JR, Amidon GL. Novel approach to the analysis of in vitro-in vivo relationships Journal of Pharmaceutical Sciences. 85: 753-760. PMID 8819002 DOI: 10.1021/js9503587  1
1996 Polli JE, Rekhi GS, Shah VP. Methods to compare dissolution profiles Drug Information Journal. 30: 1113-1120.  1
1995 Polli JE, Amidon GL. Mathematical model and dimensional analysis of glycocholate binding to cholestyramine resin: Implications for in vivo resin performance Journal of Pharmaceutical Sciences. 84: 1446-1454. PMID 8748328 DOI: 10.1002/jps.2600841212  1
1995 Polli JE, Amidon GL. In vitro characterization of sodium glycocholate binding to cholestyramine resin Journal of Pharmaceutical Sciences. 84: 55-61. PMID 7714745 DOI: 10.1002/jps.2600840114  1
Show low-probability matches.